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Background: Randomized controlled trials have established concurrent chemo-radiotherapy as the preferred
treatment option for inoperable local-regionally advanced head and neck squamous cell carcinomas (HNSCCs).
Because many patients have multiple co-morbidities and would not fulfill the eligibility criteria of clinical trials, the
results need to be re-evaluated in daily clinical practice with special reference to early mortality.
Methods: 167 consecutive patients with HNSCC who received concurrent chemo-radiotherapy at the Basel
University Hospital between 1988 and 2006 were analyzed retrospectively with a special focus on early deaths and
risk factors for an unfavorable outcome.
Results: In our cohort, the 3- and 5-year overall survival rates were 54% and 47%, respectively. The therapy was
associated with relevant toxicity and an early mortality rate of 5.4%. Patients dying early were analyzed individually
for the cause of death. Patients with elevated white blood cell counts (HR: 2.66 p = 0,016) and vascular
co-morbidities (HR: 5.3, p = 0,047) showed significantly worse survival rates. The same factors were associated with a
trend toward increased treatment-related mortality. The 3-year survival rate improved from approximately 43% for
patients treated before the year 2000 to 65% for patients treated after the year 2000 (Fisher’s exact test p = 0.01).
Conclusions: Although many patients who received concurrent chemo-radiotherapy would not have qualified for
clinical trials, the outcome was favorable and has significantly improved in recent years. However the early mortality
was slightly worse than what is described in the literature.
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Approximately 60% of patients with head and neck
squamous cell carcinomas (HNSCCs) are diagnosed with
a locally advanced stage (stages III and IV) [1]. Without
treatment, the median survival is less than 4 months [2].
Treatment of advanced-stage HNSCC remains challen-
ging. In the past, radiotherapy alone was the treatment
of choice for patients with non-resectable or inoperable
local-regional disease. Due to unsatisfactory results,* Correspondence: Martin.Buess@claraspital.ch
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reproduction in any medium, provided the orintensified radiotherapy and concurrent radiation and
chemotherapy protocols were initiated [3]. In early trials
with chemo-radiotherapy, there were no improvements
in survival, due to an increase in toxicity and therapeutic
abortions; however, radiotherapy in combination with
cis-platinum resulted in higher complete remission rates
of 65% to 70% [3-5]. In a randomized trial, the 3-year
survival rate was significantly higher for patients who
obtained concurrent chemo-radiotherapy with cis-
platinum [6] than radiotherapy alone. The advantages of
this regimen were confirmed by multiple trials [6-10],
and several meta-analyses have consistently demon-
strated that concurrent chemo-radiotherapy and, in par-
ticular, platinum-based concurrent chemo-radiotherapyral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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11 percent compared to radiotherapy alone [11]. How-
ever, the better long-term results come at the price of a
higher toxicity.
Today, in the era of targeted therapies, the combin-
ation of radiotherapy with cetuximab, a monoclonal
antibody against EGFR that is over-expressed in a major-
ity of HNSCC tumors resulted in significantly improved
survival rates compared with radiotherapy alone (55% vs.
45% after 3 years) and a better local-regional control
[12]. However, despite promising results, the role of
cetuximab in therapeutic regimens remains uncertain; as
yet, no direct comparisons of this drug to other chemo-
therapy drugs (such as cis-platinum) exist.
The improved survival rates from concurrent chemo-
radiotherapy come at the price of increased therapy-
associated morbidity due to myelosuppression, dermatitis,
mucositis, and diarrhea. The patients with numerous
co-morbidities and poor general health are particularly
vulnerable to these toxicities and might therefore be un-
suitable for this treatment option [13]. The restrictive
inclusion criteria of most trials would exclude many
HNSCC patients with co-morbidities due to chronic
alcohol and nicotine consumption. Despite representing
the majority of patients, evidence-based guidelines in
these subsets of patients with co-morbidities are largely
nonexistent. Outside of controlled trials, more frequent
discontinuations of treatment, delays in the irradiation
protocol and reductions in radiation doses occur, which
indicate that certain results obtained in trials can only
be partially transferred to the clinical practice. Thus,
concurrent chemo-radiotherapy cannot be adopted as
the standard treatment for all patients with advanced-
stage disease [14].
A number of unexpected deaths during or shortly after
concurrent chemo-radiotherapy in our clinic prompted
this analysis. The aim of our study was to analyze retro-
spectively the results of concurrent chemo-radiotherapy
in a setting outside of a prospective clinical trial at the
Basel University Hospital. Early mortality within 30 days
of therapy was of special interest. Specifically, our ques-
tions were as follows: 1. What are the results of concur-
rent chemo-radiotherapy in the cohort of locally
advanced HNSCC patients treated in the Head and Neck
Cancer Center of the Basel University Hospital? 2. How
many patients died during or within 30 days of concur-
rent chemo-radiotherapy? 3. How does this patient
population compare to the patients treated within a clin-
ical trial? 4. Are there any predictive factors for early
mortality?
Methods
A total of 167 consecutive patients who were treated at
the Interdisciplinary Head and Neck Cancer Center ofthe University Hospital of Basel were included. All pa-
tients had pathologically proven HNSCC. HPV status
was not determined. The patients had been evaluated at
the interdisciplinary tumor board by experienced spe-
cialists of the cancer center prior to treatment with con-
current chemo-radiotherapy. The relevant data were
extracted from patient charts. Before treatment, the clin-
ical, laboratory and imaging examinations were per-
formed to determine an accurate TNM stage (TNM 6th
edition) [15]. The staging procedure did not include
PET scans. During therapy, the patients were assessed at
least weekly for signs of toxicity. This retrospective ana-
lysis was approved by the ethical committee beider
Basel, Switzerland, (EKBB 360/2009).
The following data were assessed: age; sex; perform-
ance status (PS); histology; stage; smoking and alcohol
consumption history; co-morbidities (e.g. concurrent
vascular disease); laboratory values (i.e., hemoglobin
levels, leukocyte counts, and serum albumin levels); dur-
ation and type of chemotherapy and radiotherapy; radio-
logical response according to WHO criteria and overall
survival time.
Statistical analyses
To determine whether patient outcome has improved
over time, patients were divided into two cohorts of
either before or after the year 2000.
The variables related to the patients, diseases, and
treatments, were compared among cohorts using the
chi-square test for discrete variables and the Mann-
Whitney U test for continuous variables. The probabil-
ities of survival were calculated using the Kaplan-Meier
estimator. The log-rank test was used for comparing
groups. The following variables were analyzed for associ-
ation with survival:
patient characteristics (age, sex, smoking history, and
weight loss); disease characteristics (disease stage and
histology) and laboratory values (white blood cell count,
hemoglobin, and albumin).
The relative risk was calculated with the MedCalc soft-
ware; RR = a/(a + b)/c/(c + d).
Results
Patient characteristics
A total of 167 consecutive patients with HNSCC receiv-
ing concurrent chemo-radiotherapy between 1988 and
2006 at the Head and Neck Cancer Center of the Basel
University Hospital were analyzed retrospectively. The
median age was 57 years (25–82 years); 80% of the pa-
tients were male. Nicotine and/or alcohol consumption
was commonly reported. Most tumors were located in
the piriform sinus (n = 32), the base of the tongue (n =
27), the tonsils (n = 24) and in the hypopharynx (n = 20).
In 117 patients, lymph node metastases were detected:
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Figure 1 Kaplan-Meier plots of overall-survival estimates. (a) All
patients treated with concurrent chemo-radiotherapy at the Head
and Neck Cancer Center of the Basel University Hospital. The 95%
confidence interval is indicated by dotted lines (b). The patients
treated after the year 2000 (n = 72) showed an improved survival
rate with a hazard ratio of 0.526 (p = 0.0041) compared to the
patients treated before the year 2000 (n = 85).
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tients, the nodal metastasis occurred only contra-
laterally. Metastases in the lung were described in one
patient; in all other patients, no distant metastases were
documented. The staging according to the American
Joint Committee on Cancer (AJCC) resulted in 1 patient
with stage I cancer, 8 with stage II, 27 with stage III and
129 with stage IV. In the patients with stage I-III carcin-
omas, primary surgery was not performed due to consid-
erations regarding functional or cosmetic organ
preservation. Eight of the 167 patients showed a syn-
chronous secondary carcinoma. Before treatment, 36 pa-
tients (44%) had concurrent vascular disease (n = 82; for
85 patients, there were no data available). In addition, 31
patients (35%) had hemoglobin values below the normal
range (normal range: 135–175 g/l) (n = 79), 13 patients
(16%) showed increased leukocytes counts (normal
range: 4.5-11.5 g/l) (n = 79) and 33 patients (45%) had
albumin levels below the normal range (normal range:
37–51 g/l) (n = 74).
A total of 88% of patients started concurrent chemo-
radiotherapy within the first three months after diagno-
sis. Cis-platinum was the primary treatment and was
frequently used as a single agent in combination with
radiotherapy. Among patients treated with radiotherapy
and combination chemotherapy regimens, cis-platinum/
5-FU and carbo-platinum/5-FU were most frequent.
Several patients were treated in a pilot study with irradi-
ation in combination with cis-platinum and gefitinib, a
tyrosine-kinase EGFR inhibitor. The doses of radiother-
apy were above 70 Gy for most patients; 23% of patients
received a total dose of 60–70 Gy, and 14% received less
than 60 Gy. The duration of treatment was in the stand-
ard range, typically lasting 40 to 60 days.
Results of the concurrent chemo-radiotherapy
Of the 167 patients, 98 (59%) showed a complete re-
sponse, 23 (14%) had a partial remission, eight (5%)
showed no change in disease status, six (3%) showed
tumor progression, nine (5%) died during therapy, and
for 23 patients (14%), the response data were missing.
One year after diagnosis, there were 125 patients
(75%) alive, three (2%) died in the absence of a tumor
and ten (6%) died from the tumor. For six patients (4%),
there was no information available except that they did
not die while under therapy. Nine patients (5%) died
during or within 3 weeks of therapy, and there was no
information available for 14 patients (8%; n = 167). The
3-year overall survival rate was 54%, and the 5-year sur-
vival rate was 47%. The median overall survival was
44 months (range 3–204 months; Figure 1a). In recent
years, since the year 2000, concurrent chemo-
radiotherapy has improved. The median follow-up of pa-
tients who were treated after the year 2000 was 3 years,while the patients treated before the year 2000 had a
longer follow-up time. The 3-year survival rate has risen
from 43% in the years before 2000 to over 65% in the
years after 2000 (two-sided Fisher’s exact test, p = 0.01).
The patients who were treated before the year 2000
showed a median survival of 20 months, while patients
treated after the year 2000 lived longer, and the median
survival was not reached after 36 months (Figure 1b).Therapy-associated toxicity
Under therapy, approximately half of the patients suf-
fered from severe stomatitis > grade 2. The pretreatment
hemoglobin values were below the normal range (men <
140 g/l, women < 120 g/l) in 28 out of 79 patients (36%;
for 88 patients, there were no data available), and 76 out
of 84 patients (90%) developed anemia during the ther-
apy. Also, 70 out of 72 patients (97%) developed hypo-
albuminemia (< 37 g/l) during therapy. Neutropenia
occurred in 14 out of 53 patients (28%); 11 of these pa-
tients (20%) developed febrile neutropenia. Nausea and
vomiting were documented in 21 of 56 patients (37%),
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titis > grade II.Early mortality during concurrent therapy
Nine patients died during or within three weeks of
chemo-radiotherapy, resulting in an early mortality rate
of 5.4%. Three of these patients were female; the median
age was 59 years. The patients who died under therapy
had consumed an average of 54 pack-years of nicotine,
and alcohol consumption was reported for eight. The
patients dying under therapy were analyzed individually
for the cause of death; the autopsy results are summarized
in Table 1. One patient died from neutropenic infection, a
side effect of chemotherapy known to be potentially fatal.
In the other eight patients who died during therapy, we
did not find any obvious well-described complication of
concurrent chemo-radiotherapy.The prognostic impact of hemoglobin, albumin, white blood
cell counts, vascular co-morbidities, and alcohol and nico-
tine consumption
To determine whether patients who died during therapy
differed significantly from patients benefiting from treat-
ment, we compared the following parameters in the two
populations: pre-therapeutic hemoglobin levels, white
blood cell counts, albumin levels, the presence of vascu-
lar co-morbidities, and nicotine and alcohol consump-
tion. The first question was whether these factors have a
prognostic significance. In patients with elevated white
blood cell counts before treatment, the median survival
was 20 months compared to 39 months for patients with
normal white blood cell counts; this result indicated a
significant difference (n = 74, HR = 2.66, P = 0,016).
Anemia before initiating therapy reduced the median
survival to 30.5 months compared to 37 months in pa-
tients with normal hemoglobin levels (n = 79, HR = 1.53,
p = 0.25). The patients with hypoalbuminemia before
therapy showed a median overall survival of 38 monthsTable 1 A summary of the causes of death while under
therapy
Cause of death:
Case 1 heart failure
Case 2 heart failure
Case 3 aspiration pneumonia
Case 4 liver failure
Case 5 Unknown (no autopsy)
Case 6 heart failure
Case 7 myocardial infarction
Case 8 protracted shock
Case 9 ischemia of the small bowelcompared to 40 months in patients with normal albumin
levels (n = 56, HR = 2.28, p = 0,082). The patients with
vascular co-morbidities prior to therapy showed a me-
dian survival of 21.5 months compared to 42 months
(n = 30, HR = 5.3, p = 0.047). The patients with alcohol
use before starting treatment showed a 24-month me-
dian survival compared to those without alcohol abuse
who had a median survival of 48 months, which was
not a significant difference (n = 138, HR = 1.25, p = 0.32)
(Figure 2).
A description of risk factors associated with death while
under therapy
To select patients for chemo-radiotherapy, we were in-
terested in factors predicting an early death while under
therapy. To this end, we analyzed whether vascular co-
morbidity, alcohol, nicotine, hemoglobin and albumin
levels distinguished patients who died under treatment
from patients who benefited with a long survival. Vascu-
lar co-morbidities were present in 75% of the deceased
patients compared to 40% of the remaining patients
(p = 0.09). In addition, 90% of the patients who died under
therapy consumed alcohol, whereas only 60% of the pa-
tients who benefitted from therapy consumed alcohol
(p = 0.11). Furthermore, 90% of the patients who died
under therapy smoked on average 54 pack-years. Before
the initiation of therapy, one third of the deceased later
showed anemia, whereas the remaining patients were af-
fected only by 33% (p = 0.09). The albumin levels were low
in 60% of the patients who died under therapy and in 40%
of the remaining patients (p = 0.29). Therefore, none of
these factors was significantly associated with death while
under therapy. The data are summarized in Table 2. High
alcohol consumption showed a trend toward predicting
therapy-associated mortality.
Discussion
In our institution, the 3-year survival rate of locally ad-
vanced HNSCC after concurrent chemo-radiotherapy
was 54%. This result is comparable to the results ob-
tained within the relevant clinical trials (Table 3)
[6-10,12,16-18]. Thus, it appears that the therapeutic re-
sults of our patient cohort outside of a clinical trial lie
within the average range of the results from the pub-
lished clinical trials. Importantly, in recent years, the
therapeutic results of our institution have improved sig-
nificantly. The patients treated after the year 2000 had a
survival rate of 65%, and those treated before the year
2000 showed a survival rate of 43% at 3 years (HR 0.526,
p = 0.0041). Today, the survival rate of 65% at 3 years
compares well with the data from published clinical
trials.
A main cause for the better survival rates in the cohort
treated after the year 2000 might be the improved
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Figure 2 The prognostic impact of hemoglobin levels, leukocyte counts, albumin levels, vascular co-morbidities and alcohol
consumption. The patient overall survival depends on (a) hemoglobin levels (HR 1.53; p = 0.25), (b) leukocyte counts (HR 2.26; P = 0.016),
(c) pre-therapeutic albumin levels (HR 2.28; p = 0.082), (d) vascular risk factors (HR 5.3; p = 0.047) and (e) alcohol consumption (HR 1.25; p = 0.32).
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CRT (3-dimensional conformal radiotherapy) with iso-
centric CT-planning at our institute in the year 2001
with maximum dose levels of up to 74 Gy in the tumor
area replacing the 2D-SSD technique. The dose prescrip-
tion pertains to the appropriate PTV area: 74 Gy to the
primary tumor and macroscopically positive lymph
nodes (boost area). Per definition the CTV area covers
all macroscopic disease (tumor and positive lymph-
nodes). The CTV is the area at risk of microscopic in-
volvement. The PTV is a safety margin that is added to
the CTV to allow for set-up errors and movement. In
general the ipsilateral nodal drainage areas were treated
with 56 Gy and the contralateral drainage areas with
50 Gy.
None of the patients was treated with IMRT (intensity
modulated ratiotherapy). Other potential reasons for
improvement in outcome such as chemotherapy sched-
ules and doses could not be evaluated in this retrospect-
ive study. Furthermore, the results with respect to
overall survival appear to support the selection strategy
applied by the interdisciplinary head and neck cancer
center team. Of note, outside of a setting with anexperienced interdisciplinary team, the results might
differ significantly.
Comparison of therapy-associated mortality
Nine out of 167 patients died during or within 30 days
after completion of therapy, an observation that led to
the initiation of this retrospective analysis. Our hypoth-
esis was that the rate of early mortality might be too
high in our institution. Examining the above mentioned
trials with respect to early death rates, we obtained the
information as shown in Table 3. These results indicate
that compared to these trials, our cohort ranged within
the 95-99% worst values. This is not surprising in a pa-
tient population outside of a clinical trial for which usu-
ally less rigid criteria are applied to exclude a patient
from the treatment.
Comparison of the eligibility criteria
To identify differences between our HNSCC population
and the patients treated within the relevant clinical tri-
als, the eligibility criteria have been analyzed. In the trial
by Bernier et al. [18], patients with anemia (<110 g/l)
were excluded from the trial. This restriction indicates
Table 2 The potential risk factors and their association
with death under concurrent chemo-radiotherapy
Predictive factors for early death under therapy
Dead Alive Relative risk p-value
Vascular co-morbidities
Present 6 30 3.83 0.09
Absent 2 44
No data 1 84
Alcohol consumption




Yes 8 86 6.2 0.081
No 1 72
Hemoglobin
Below normal range 6 25 3.09 0.09
Normal 3 45
No data 0 88
Albumin
Below normal range 5 28 2.07 0.29
Normal 3 38
No data 1 92
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our cohort would have been excluded from this treat-
ment approach. However, 25 of 70 patients (35%) who
survived the treatment would have also been excluded
and would have missed the benefits of chemo-
radiotherapy. In the same trial, the age limit was set toTable 3 A cross-study comparison of long term survival data
Basel and patients with HNSCC who had been treated within
chemo-radiotherapy
Study Year 3-OS (in %
Bonner et. al. 2006 55
Huguenin et. al. 2004 59°
Calais et. al. 1999 51
Merlano et. al. 1996 38*
Adelstein et. al. 2000 37
Wendt et. al. 1998 49
Brizel et. al. 1998 55
Al-Sarraf et. al. 1998 78
Data from Basel 1994-2007 54
- Therapy before 2000 43
- Therapy after 2000 65
°Survival after 2.5 years.
*estimated value.70 years; 17 of our patients would not have qualified due
to the age restriction and one of the patients over
70 years died under therapy. In total, five out of our nine
patients who died under treatment would not have met
the 2 abovementioned inclusion criteria and therefore
would not have been eligible for the treatment according
to the trial. In the study by Bonner et al. [12], normal
hematological, hepatic and renal function were a pre-
requisite for the treatment, which would have excluded
50 of our patients. According to this study, 6 out of the
9 patients who died under treatment would not have
met the eligibility criteria and thus would have been ex-
cluded. These comparisons show that our patients repre-
sent a different population from that of the clinical trials
and are characterized by increased co-morbidities and
risk factors, thereby explaining the larger treatment-
associated mortality. Overall, the eligibility criteria
within the clinical trial protocols were safer; however,
they also excluded many patients who successfully com-
pleted the treatment and appear to have benefited from
this therapeutic approach. Although patient selection
was based on the decisions of an experienced interdis-
ciplinary team, a higher number of early deaths during
therapy was observed, supporting the notion that a
checklist of inclusion and exclusion criteria, as used in
the clinical trial setting, would be a safe way to minimize
early deaths. Despite the fact that many patients who
were treated at University Hospital in Basel would never
have fulfilled the inclusion criteria of a clinical trial, the
3-year survival data were comparable to the results from
the published clinical trials in a patient collective that
was considerably larger than the highly selected trial
population. This finding indicates that the rigid selection
of a clinical trial also eliminates many patients whoand early death rates of the patients with HNSCC from
published clinical trials with concurrent
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with early deaths died due to treatment complications or
due to the disease or co-morbidities cannot be definitely
decided in a single-arm study. The question remains of
whether a higher early mortality risk is considered ac-
ceptable in view of the favorable overall survival results
of a cohort with less stringent patient selection.
Unfortunately, among all of the factors analyzed for
prognostic value, none was significantly associated with
early death, and we could not identify any predictive
marker for therapy-associated mortality.
Conclusions
Despite having a rather high early mortality rate, the
overall outcome of our cohort of HNSCC patients
treated with concurrent chemo-radiotherapy is favorable
and has improved in recent years. Because our study did
not reveal significant predictive markers for early fatal
outcomes, we suggest for the moment not to withhold
concurrent chemo-radiotherapy based only on such a
marker. However, these risk factors should give rise to
greater caution and be discussed with patients before
therapy. In conclusion, the analyses of our data con-
firmed that chemo-radiotherapy performed by an experi-
enced team can reach similar results in a population
outside of a clinical trial and that considerable progress
has been made with the use of concurrent chemo-
radiotherapy to treat HNSCC over the last decade. An
experienced team is necessary to perform the treatments
and manage the therapy-associated toxicities.
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